FDA Gives Green Light to Biogen's Alzheimer’s Drug

The transcript discusses the FDA's controversial approval of Biogen's Alzheimer's drug, highlighting the complexities and uncertainties of the evidence. It explains the drug's purpose to slow cognitive decline, its side effects, and the financial implications. The approval has significant market implications, potentially lowering the bar for future drug approvals. The need for post-approval trials is emphasized, though enforcement is often lax. The discussion also covers the massive market size and the urgent need for effective Alzheimer's treatments.

What is the significance of the post-approval study required by the FDA?

What challenges do drug companies face in conducting post-approval trials?

How large is the market for Alzheimer's treatments in the US?